Artiva Biotherapeutics (ARTV) CFO Huston Allen submits initial Form 3

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. executive Huston Thad Allen, the company’s Chief Financial Officer, filed an initial ownership report on Form 3 for ARTV. The filing lists him as an officer and does not report any share transactions, serving as a baseline disclosure of his status as an insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 02/24/2026 - 05:15 PM Learn about SEC filing dates

FAQ

What does the Artiva Biotherapeutics (ARTV) Form 3 filing report?

The Form 3 filing reports that Huston Thad Allen is an officer of Artiva Biotherapeutics and serves as Chief Financial Officer. It is an initial statement of beneficial ownership and, in this case, shows no reported share transactions.

Who is the insider named in the Artiva Biotherapeutics (ARTV) Form 3?

The insider is Huston Thad Allen, who is identified as Chief Financial Officer of Artiva Biotherapeutics. He is reported as an officer, not a director or 10% owner, establishing his status as a reporting person under insider rules.

Does the Artiva Biotherapeutics (ARTV) Form 3 show any stock transactions?

The Form 3 shows no stock transactions for Huston Thad Allen, with zero buy, sell, acquire, or dispose activities reported. It functions only as an initial ownership and status disclosure, not as a record of trades.

Is Huston Thad Allen a 10% owner of Artiva Biotherapeutics (ARTV)?

No, the Form 3 indicates Huston Thad Allen is not a 10% owner of Artiva Biotherapeutics. He is listed solely as an officer, serving as Chief Financial Officer, with no 10% ownership box checked in the filing.

Why is a Form 3 important for Artiva Biotherapeutics (ARTV) insiders?

Form 3 is important because it establishes an insider’s initial beneficial ownership status when they become subject to reporting. For Artiva Biotherapeutics, Huston Thad Allen’s filing confirms his role as Chief Financial Officer under insider reporting rules.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huston Thad Allen

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/18/2026

3. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.